Dear Duchenne Community, We are proud that, through these difficult times, CureDuchenne is continuing to invest in research, to expand our programs and offer services to the Duchenne Community. All of us are feeling the personal, emotional and financial toll […]
In this webinar, moderated by Tiffany Cook, MS, CCC-SLP, Senior Director of CureDuchenne Cares, the mental health presentation by Paige Lembeck, PhD, will be followed by several presentations from biopharmaceutical companies […]
Author: Erin Frey, Senior Director of Advocacy, CureDuchenne Watching the news over the last few weeks has ranged from confusing to disheartening, overwhelming and sometimes, let’s admit it, a little […]
Today, we are extremely excited to announce a new partnership with Dyne Therapeutics, an innovative organization whose FORCE™ Platform is working to bring transformational therapies for serious muscle diseases, including […]
WALTHAM, Mass., March 31, 2020 – Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced an equity investment from CureDuchenne Ventures. The funding […]
NEWPORT BEACH, Calif., (March 24, 2020) – CureDuchenne, the leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, is rolling out a comprehensive suite of online resources for […]
View Letter to the Duchenne Community As recently as March 9, CureDuchenne was helping NS Pharma get the word out about their newly launched Expanded Access Program for enabling access […]
THE CURRENT ADVICE FROM THE PROFESSIONAL SOCIETIES IS TO CONTINUE WITH ACE-I AND ARBS. The European Society of Cardiology (ESC) Council on Hypertension announced their stance in a positioning statement […]
As a mom, a family, a friend, an advocate and a community, we know that the spread of the coronavirus disease 2019 (COVID-19) is clearly creating challenging times that call […]
